HOME >> MEDICINE >> NEWS
Osteoporosis drug rapidly reduces risk of bone fractures: one year of treatmentsignificantly decreases occurence of spinal fractures

Based on recent findings from the largest osteoporosis study to date, researchers at UC San Francisco are calling an investigational drug for postmenopausal women an excellent new weapon in the fight against osteoporosis. In a placebo-controlled study of 2,458 post-menopausal women with osteoporosis, researchers found that after three years of treatment with the drug, called risedronate, the incidence of new fractures of the spine (vertebral) was reduced by 41 percent and non-vertebral fractures by 39 percent among women taking risedronate compared to those receiving a placebo.

As further indication of the drug's effectiveness, after just one year of treatment with risedronate, the incidence of new spinal fractures was reduced by 65 percent among women in the risedronate group compared to those in the placebo group.

The study is published in the October 13 issue of the Journal of American Medical Association.

"Risedronate has also been shown to increase bone mass, stop bone loss, and produce healthy bones in women with established postmenopausal osteoporosis," said Steven T. Harris, MD, chief of the Osteoporosis Clinic at UC San Francisco and lead author of the study.

The bone mineral density (BMD) of women in the study who received risedronate increased significantly compared to those who took a placebo. BMD increased at the spine (5.4% versus 1.1%); neck (1.6% versus -1.2%); hip (3.3% versus -0.7%); and forearm (0.2% versus -1.4%), Harris said.

He added that risedronate was also well tolerated among study participants. Although upper gastrointestinal (GI) problems are common in older women, the incidence of GI problems was the same among women in the risedronate and placebo groups.

Women who participated in the study were postmenopausal with at least one previous vertebral fracture. During the three-year, randomized, double-blind, multicenter trial (110 study centers in North America) participants were randomized to recei
'"/>

Contact: Abby Sinnott
asinnott@pubaff.ucsf.edu
415-885-7277
University of California - San Francisco
12-Oct-1999


Page: 1 2

Related medicine news :

1. Advances in Skeletal Anabolic Agents for the Treatment of Osteoporosis: A scientific meeting
2. ACP-ASIM books program publishes Osteoporosis
3. Osteoporosis is costly for Californians, according to UCSF researchers
4. News About Osteoporosis: Fruits And Vegetables Prevent Bone Decay
5. UCSF Study Shows Drug Reduces Risk Of Spine And Hip Fractures By Half In Women With Osteoporosis
6. Osteoporosis Drug Evista (Raloxifene) Cuts Newly Diagnosed, Invasive Breast Cancer Risk By More Than 60 Percent
7. Signal Pharmaceuticals Announces Positive Results In Preclinical Study Of Novel Drug Leads For Treatment Of Osteoporosis
8. UNC-CH Studies Show Medicine Can Reverse Osteoporosis From Transplants, Cystic Fibrosis
9. Study Shows Calcitonin-Salmon Nasal Spray Helps Prevent New Spinal Fractures In Women With Existing Osteoporosis
10. Studies Indicate An Effective Treatment For Steroid-Induced Osteoporosis
11. Studies address issues of risk and survival in rapidly increasing GI cancers

Post Your Comments:
(Date:6/18/2013)... (PRWEB) June 19, 2013 Looking for a ... monotony of everyday life? , IWALKAWAKE is a guide ... Written by Adam Botha, it focuses on harnessing the powerful ... The book lays out a nine-step guide to finding one’s ... that a person must go through to reach their true ...
(Date:6/18/2013)... Daily Gossip Magazine has always kept its readers entertained ... , The magazine has decided to prepare readers for the ... recipe every week . , According to Daily Gossip ... readers who are looking to get insights into this type ... anabolic food is almost entirely based on healthy, yet tasteful ...
(Date:6/18/2013)... (PRWEB) June 18, 2013 SEATTLE, WA—A ... Farms of Fairview, Oregon, claiming he fell ill with ... berry and pomegranate seed blend. The complaint was ... by Marler Clark, the Seattle-based law firm that has ... , According to the complaint, Brian Brothers consumed “Townsend ...
(Date:6/18/2013)... Warner, NH (PRWEB) June 18, 2013 ... rugged, submersible, battery powered, stand-alone device which can be ... The new stainless steel enclosure of the Temp1000IS comes ... device interfaces with the IFC400 (sold separately) ... docking station for full communications. No more removal of ...
(Date:6/18/2013)... Senior drug regulatory officials from mainland China and Taiwan ... first time in the U.S.—the need for more collaboration between ... in a timely manner. Representatives from the Taiwan and mainland ... and processes in drug review during the Convergence in ... DIA 2013 49th Annual Meeting . , While ...
Breaking Medicine News(10 mins):Health News:Anabolic Cooking Book Review Exposes Dave Ruel’s Top 10 ‘Anabolicious’ Recipes for BodyBuilders 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 2Health News:Marler Clark, Washington Resident Sue Townsend Farms Over Hepatitis A 3Health News:MadgeTech, Inc. Introduces the New Temp1000IS Intrinsically Safe High Temperature Data Logger 2Health News:Renowned Regulatory Representatives From Mainland China and Taiwan to Discuss Need for Collaboration at DIA Meeting 2
(Date:6/18/2013)... , Safinamide significantly improves ... as add-on to levodopa Safinamide is ... in fluctuating PD patients as add-on to levodopa ... ("Newron"), a research and development company focused on ... Zambon S.p.A., a pharmaceutical company strongly committed to ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
(Date:6/18/2013)... 2013  Intercept Pharmaceuticals, Inc.  (NASDAQ: ICPT ... development and commercialization of novel bile acid therapeutics to ... an underwritten public offering of 1,730,000 shares of its ... per share.  In addition, Intercept has granted the underwriters ... 259,500 shares of common stock. All of ...
Breaking Medicine Technology:Safinamide Phase III Study Results Presented at 2013 MDS Meeting 2Safinamide Phase III Study Results Presented at 2013 MDS Meeting 3Safinamide Phase III Study Results Presented at 2013 MDS Meeting 4Safinamide Phase III Study Results Presented at 2013 MDS Meeting 5Safinamide Phase III Study Results Presented at 2013 MDS Meeting 6Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: